source
- Corxel to go public via $300 million SPAC merger, advancing GLP-1 pill CX11 and amylin candidateCorxel Pharmaceuticals announced it will become a public company by merging with the SPAC Amanat Acquisition Corp., accompanied by a $300 million private investment. The transaction will fund the…
- J&J's Halda-derived prostate cancer drug shows 75% response in early Phase 1 trialJohnson & Johnson's recent $3 billion purchase of Halda Therapeutics added an oral prostate cancer candidate, JNJ-6143, to its pipeline. The drug targets a cancer-specific protein to trigger cell d…